Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP02 vs Irinotecan in Metastatic Colorectal Cancer (PEPCOL)
NCT01375816Phase 2Terminated
- Sponsor
- GERCOR
- Start
- May 2011
- Primary completion
- Jun 2014
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in colorectal cancer (metastatic) (mCRC), sponsored by GERCOR. Started May 2011; status: terminated.
02
Drugs
nanoliposomal irinotecan
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01375816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01375816.